Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone
Authors
Keywords
-
Journal
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
Volume 29, Issue 1, Pages 38-45
Publisher
Wiley
Online
2013-11-26
DOI
10.1002/hup.2366
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study
- (2012) Yuejin Chen et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Cardiometabolic risk and the MTHFR C677T variant in children treated with second-generation antipsychotics
- (2012) A M Devlin et al. Translational Psychiatry
- Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review
- (2012) Gavin P. Reynolds Clinical Psychopharmacology and Neuroscience
- Polymorphisms of INSIG2, MC4R, and LEP Are Associated With Obesity- and Metabolic-Related Traits in Schizophrenic Patients
- (2011) Po-Hsiu Kuo et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications
- (2011) T A P Lett et al. MOLECULAR PSYCHIATRY
- Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting
- (2011) Jochem G Gregoor et al. PHARMACOGENOMICS
- Association of the ADRA1A gene and the severity of metabolic abnormalities in patients with schizophrenia
- (2011) Chin Cheng et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Effectiveness of Switching From Aripiprazole to Ziprasidone in Patients With Schizophrenia
- (2010) Sung-Wan Kim et al. CLINICAL NEUROPHARMACOLOGY
- MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study
- (2010) Ruud van Winkel et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Association Between the 1291-C/G Polymorphism in the Adrenergic α-2a Receptor and the Metabolic Syndrome
- (2010) Arne J. Risselada et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Potential mechanisms of atypical antipsychotic-induced metabolic derangement: Clues for understanding obesity and novel drug design
- (2010) Roberto Coccurello et al. PHARMACOLOGY & THERAPEUTICS
- MTHFR and risk of metabolic syndrome in patients with schizophrenia
- (2010) Ruud van Winkel et al. SCHIZOPHRENIA RESEARCH
- Antipsychotic drugs and obesity
- (2010) Christoph U. Correll et al. TRENDS IN MOLECULAR MEDICINE
- Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
- (2009) S. M. Stahl et al. ACTA PSYCHIATRICA SCANDINAVICA
- Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study
- (2009) Koksal Alptekin et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Association of the α2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European–Americans
- (2009) Laertes Sickert et al. PHARMACOGENOMICS
- Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms
- (2009) Gavin P Reynolds et al. PHARMACOLOGY & THERAPEUTICS
- Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study
- (2009) Hiroyoshi Takeuchi et al. PSYCHIATRY AND CLINICAL NEUROSCIENCES
- Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone
- (2008) Alessandro Rossi et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants
- (2008) Vicki L. Ellingrod et al. SCHIZOPHRENIA RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now